In vivo Evaluation of Substituted 3-Amino-1,4-benzodiazepines as Anti-depressant, Anxiolytic and Anti-nociceptive Agents

Abstract

Oxazepam (CAS 604-75-1) 4a served as building block in the synthesis of substituted 3-amino-1,4-benzodiazepines, which were subsequently tested in various CNS animal models. The hydroxy group of oxazepam was either activated as a chloride (Method A) or as a phosphor-oxy derivative (Method B) giving the desired 3-amino-1,4-benzodiapines 6a–6r in high yields with primary and secondary amines in a typical nucleophilic substitution reaction. Eighteen 3-substituted 1,4-benzodiazepines were prepared and served as new chemical entities and for lead structure discovery. The mixed cholecystokinin (CCK) antagonist 6e showed anxiolytic and antidepressant effects from 10 μg/kg in mice in the elevated x-maze test and the forced swimming test. The CCK₁ antagonist 6 g has shown antidepressant effects from the same dose, but lacked anxiolytic properties. Both compounds potentiated at a dose of 0.5 mg/kg morphine antinociception with a maximum possible effect (MPE) about 35%. By assessing initially the MPE of antinocipection for the 18 newly synthesised benzodiazepines in the tail-flick test, 4 other benzodiazepines were found active. In further in vivo evaluation the cyclohexyl derivative 6i displayed anxiolytic, antidepressant and antinociceptive properties as single agent at a dose of 5 mg/kg without toxicity. The benzodiazepines 6i and 6p, which initially showed a higher MPE in terms of morphine potentiation (43/44%) showed analgesic effects as single agents, without having anxiolytic or antidepressant properties.

The amino-piperidinyl derivative 6p displayed a similar dose-response relationship to morphine, but was 3 times more potent.

Key words

3-Amino-5-phenyl-l,4-benzodiazepinone - Antidepressants - Antinociceptives - Anxiolytics - 1,4-Benzodiazepines, template - CAS 604-75-1 - Cholecystokinin antagonists - Oxazepam

• References

• 1 Martin IL, Lattmann E. Benzodiazepine recognition site ligands and GABA_A receptors. Exp Opin Ther Patents. 1999; 9: 1347-52
• 2 Lattmann E, Billington DC, Poyner DR. Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists. Drug Des Discov. 2001; 17: 219-32
• 3 Wilson TM, Henke BR, Momtahen TM. 3-[2-(N-Phenylacetamide)]-l,5-benzodiazepines: Orally active, binding selective CCK-A agonists. J Med Chem. 1996; 39: 3030-8
• 4 Showell GA, Bourrain S, Neduvelil JG. High affinity and potent, water soluble 5-amino-1,4-benzodiazepine CCK_B/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem. 1994; 37: 719-31
• 5 Wood MR, Homnick CF, Murphy KL. Benzodiazepines as potent and selective bradykinin Bl antagonists. J Med Chem. 2003; 46: 1803-17
• 6 Varty GBP, Ursula C, Galen J. The gerbil elevated plusmaze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology. 2002; 27: 371-84
• 7 Sansone M, Castellano C, Pavone F. Opioid benzodizapine tifluadom and drug-induced hyperactivity in mice-lack of benzodiazepine-like effects. Pol J Pharmacol Pharm. 1985; 37: 585-91
• 8 Petrillo P, Amato M, Tavani A. The interaction of the two isomers of the opioid benzodiazepine tifluadom with binding sites and their analgesic and intestinal effects in rats. Neuropeptides. 1985; 5: 403-11
• 9 Lattmann E, Offel M, Singh H Aston University, PCT/GB2004/002252, 27/05/2004.
• 10 Roskoski R, Ritchie PA. Time-dependent inhibition of protein tarnesyl-transferase by a benzodiazepine peptide mimetic. Biochemistry. 2001; 40: 9329-35
• 11 Sternbach LH, Reeder E. (F. Hoffmann-La Roche AG), Swiss Patent 2.233.482, 11/12/1960.
• 12 Stempel A, Douvan I, Reeder E. Quinazolines and 1,4-benzodiazepines. 4,l,5-benzoxadiazocin-2-ones, a novel ring system. J Org Chem. 1967; 32: 2417-22
• 13 Sternbach LH, Reeder E. Quinazolines and 1,4-benzodiazepines. The rearrangement of 6-chloro-2-chloromethyl-4-phenylquinazoline 3-oxide into 2-amino derivatives of 7-chloro-5-phenyl-3H-1,4-benzodiazepine 4-oxide. J Org Chem. 1961; 26: 1111-8
• 14 Avadagic A, Lesac A, Majer Z. Oxidation of quinazolines and 1,4-benzodiazepines. Helv Chim Acta. 1988; 81: 1567-77
• 15 Cepanec I, Litvic M, Pogorelic I. Efficient synthesis of 3-hydroxy-1,4-benzodiazepines oxazepam and lorazepam by new acetoxylation reaction of 3-position of 1,4-benzodiazepine ring. Org Proc Res Dev. 2006; 10: 1192-201
• 16 Stempel A, Reeder E, Sternbach LH. Quinazolines and 1,4-benzodiazepines. Mechanism for ring enlargement of quinazoline 3-oxide with alkali to l,4-benzodiazepin-2-one 4-oxides. J Org Chem. 1965; 30: 4267-73
• 17 Stempel A, Douvan I, Reeder E. Quinazolines and 1,4-benzodiazepines. l,5-benzoxadiazocin-2-ones, a novel ring system. J. Org. Chem. 1967; 32: 2417-24
• 18 Satoh M, Okamoto Y, Koshio H. Biological Activity of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin-cholecystokinin-B receptor agonists. Chem Pharm Bull. 1996; 44: 1412-20
• 19 Kulkarni YD, Abdi SHR, Sharma VL. Synthesis of 3-substituted-amino/arcyloxy-7-chloro-5-phenyl-l,3-dihydro-2H-l,1,4-benzodiazepin-2-ones as possible anxiolytics. J Indian Chem Soc. 1986; 425-31
• 20 Gatta F, Delgiudice MR, Settimj G. New synthesis of 3-(disubstituted-amino)-l,4-benzodiazepin-2-ones. Chem Comm. 1979; 32: 718-25
• 21 Bock MG, DiPardo RM, Evans BE. Benzodiazepine gastrin and brain cholecystokinin receptor ligands. J Med Chem. 1989; 32: 13-26
• 22 Gatta F, Delgiudice MR, Pandolfi C. Sintesi di 2-E 3-amino 1,4-benzodizepine. Farmaco. 1982; 27: 343-51
• 23 Offel M, Lattmann P, Singh H. Synthesis of substituted 3-anilino-5-phenyl-l,3-dihydro-2H-l,4-benzodiazepinones and their evaluation as cholecystokinin ligands. Arch Pharm. 2006; 339: 163-78
• 24 Lattmann E, Billington DC, Poyner DR. Combinatorial solid phase synthesis of multiply-substituted 1,4-benzodiazepines and affinity studies on the CCK2 receptor. Drug Des Discov. 2002; 18: 9-21
• 25 Lattmann E, Singh H, Boonprakob Y. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-lH-pyrazo1-4-yl)-lH-indolecarboxamide as cholecystokinin antagonists. J Pharm Pharm. 2006; 58: 1-17
• 26 Lattmann E, Sattayasai J, Boonprakob Y. Synthesis and evaluation of N-(5-methyl-3-oxol,2-diphenyl-2,3-dihydro-lH-pyrazol-4yl)-N-phenylureas as cholecystokinin antagonists. Arzneimittelforschung. 2005; 55: 251-64
• 27 McCleane GJ. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine. Clin J Pain. 2003; 19: 200-4
• 28 McCleane GJ. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett. 2003; 338: 151-63
• 29 Simpson K Management of neuropathic pain using a CCK antagonist devazepide as an adjunct to strong opiates [abstract]. In: International conference on the mechanism and treatment of neuropathic pain; 2001; San Francisco, p. 397, no. 118.